Anlon Healthcare IPO is a book-built issue worth ₹121.03 crore. The issue consists entirely of a fresh issue of 1.33 crore shares, raising the full amount through equity. The IPO will open for subscription on August 26, 2025, and close on August 29, 2025.
The basis of allotment is expected to be finalised on September 1, 2025, with tentative listing scheduled on BSE and NSE for September 3, 2025. The price band for the Anlon Healthcare IPO has been fixed between ₹86.00 and ₹91.00 per share.
Investors can bid in a minimum lot size of 164 shares. For retail investors, the minimum investment required is ₹14,104. For small non-institutional investors (sNII), the lot size stands at 14 lots, equal to 2,296 shares, amounting to ₹2,08,936.
For big non-institutional investors (bNII), the lot size is 68 lots, which translates to 11,152 shares, requiring an investment of ₹10,14,832. Interactive Financial Services Limited is the book running lead manager for the issue, while Kfin Technologies Limited is the registrar. Detailed information is available in the Anlon Healthcare IPO RHP.
Industry Outlook
- The Indian pharmaceutical industry is projected to grow from INR 3,281 billion in FY 2021 to INR 4,741 billion in FY 2025, reflecting a 10% CAGR. This steady growth highlights rising global demand for Indian medicines.
- Europe has become a strong export market, with shipments rising from INR 192 billion in FY 2021 to INR 322 billion in FY 2025, marking a 14% CAGR. Countries like the UK, Germany, and France drive this demand.
- India supplies 60% of the world’s vaccines and nearly 80% of global antiretroviral drugs, strengthening its position as the “pharmacy of the world.” With India’s reputation for high-quality generics and vaccines, Anlon is well-positioned to build on the sector’s strength, scale its operations, and increase its presence in international markets.
Anlon Healthcare IPO Objectives
The company plans to allocate the net proceeds from the issuance to the following purposes:
- Funding manufacturing facility expansion to enhance production capacity and support future growth.
- Repayment or prepayment of secured term loans to reduce financial burden and strengthen the balance sheet.
- Meeting working capital needs to ensure smooth day-to-day operations and business efficiency.
- Allocating funds for general corporate purposes to maintain flexibility and support strategic initiatives.
About Anlon Healthcare Limited
Anlon Healthcare Limited is a chemical manufacturing company that focuses on producing high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These form the backbone of medicines such as tablets, capsules, syrups, ointments, and also play a role in nutraceuticals, personal care products, and veterinary health.
The company’s APIs are manufactured in line with Indian and global pharmacopeia standards, ensuring high quality and compliance. One of the company’s notable achievements is being among the few manufacturers of Loxoprofen Sodium Dihydrate in India, a widely used API for managing pain and inflammation in conditions like arthritis, post-surgery recovery, and tooth pain.
Anlon Healthcare has also ventured into custom manufacturing of complex chemical compounds, offering tailored solutions that exceed industry purity benchmarks. The company has filed multiple Drug Master Files (DMFs) across global markets and received approvals from regulatory agencies in Brazil, China, and Japan.
Its product portfolio includes over 65 commercialised products, along with several others in pilot and testing stages. Anlon Healthcare operates through a modern manufacturing facility in Rajkot, Gujarat, equipped with advanced reactors, laboratories, and storage systems. The plant has approvals from global regulators and is compliant with GMP and ISO standards.
Exports form a growing part of the business, with products supplied to more than 15 countries, including Italy, Germany, South Korea, Japan, and Brazil. Backed by experienced promoters and a skilled workforce, Anlon Healthcare continues to expand its global footprint while delivering high-quality pharmaceutical solutions.
How To Check the Allotment Status of Anlon Healthcare IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
How To Apply for the Anlon Healthcare IPO Online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Anlon Healthcare IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
Contact Details of Anlon Healthcare IPO
Registered office: 101/102, Silvercoin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot –360 005, Gujarat, India
Phone: +91 281 2562538/39
E-mail: cs@anloncro.com
Anlon Healthcare IPO Reservation
|
Investor Category |
Shares Offered |
|
QIB Shares |
Not less than 75% of the Issue |
|
Retail Shares |
Not more than 10% of the Issue |
|
NII Shares |
Not Less than 15% of the Issue |
Anlon Healthcare IPO Lot Size Details
|
Application |
Lots |
Shares |
Amount |
|
Retail (Min) |
1 |
164 |
₹14,924 |
|
Retail (Max) |
13 |
2,132 |
₹1,94,012 |
|
S-HNI (Min) |
14 |
2,296 |
₹2,08,936 |
|
S-HNI (Max) |
67 |
10,988 |
₹9,99,908 |
|
B-HNI (Min) |
68 |
11,152 |
₹10,14,832 |
Anlon Healthcare IPO Promoter Holding
The promoters of the company include Punitkumar R. Rasadia, Meet Atulkumar Vachhani and Mamata Punitkumar Rasadia.
|
Share Holding Pre-Issue |
70.26% |
|
Share Holding Post Issue  |
- |
Note: Equity dilution will be determined by subtracting the Shareholding Post Issue from the Shareholding Pre Issue.
Key Performance Indicators for Anlon Healthcare IPO
|
KPI |
Value |
|
ROE (%) |
40.45 |
|
RoCE (%) |
21.93 |
|
Debt/Equity  |
0.73 |
|
PAT Margin (%) |
17.06 |
|
EBITDA Margin (%) |
26.88 |
Anlon Healthcare IPO Prospectus
Anlon Healthcare IPO Registrar and Lead Managers
Anlon Healthcare IPO Lead Managers
- Interactive Financial Services Limited
Registrar for Anlon Healthcare IPO
Kfin Technologies Limited
- Contact Number: 04067162222, 04079611000
- Email Address: ipo@kfintech.com
Anlon Healthcare IPO Registrar
Financial Performance of Anlon Healthcare Limited
| Particulars | Year ending on March 31, 2025 | Year ending on March 31, 2024 |
|---|---|---|
| Revenue from Operation (in ₹ lakh) | 12,028.66 | 6,658.37 |
| Profit/loss After Tax (in ₹ lakh) | 2,051.79 | 965.71 |
| Current Ratio (x) | 2.64 | 2.01 |
| Net Worth (in ₹ lakh) | 8,042.17 | 2,103.14 |
| Return on Equity (%) | 40.45 | 67.99 |
| Return on Capital Employed (RoCE) (%) | 21.93 | 16.29 |
| EBITDA (in ₹ lakh) | 3,237.73 | 1,556.94 |
Know before investing
Strengths
8Anlon Healthcare offers over 65 commercialised products ensuring a strong product portfolio.
The company maintains 28 pilot-stage products and 49 lab-testing stage products.
Expertise in manufacturing APIs and intermediates strengthens business presence in healthcare.
Strong customer base built on trust, quality products, and customer-centric approach.
In-house QA, QC, and four R&D labs ensure stringent quality control.
Experienced promoters and management team provide a solid foundation for growth.
Operating in high entry barriers, the industry secures long-term competitive market positioning.
Scalable business model with continuous expansion across new healthcare product segments.
Risks
8Non-compliance with stringent audits can cause order cancellations and reputational harm.
Facility shutdown lasted four months earlier, showing risks of operational disruptions.
Over 65 products face risks if evolving pharmacopeia standards aren’t maintained.
Limited operating history since 2017 weakens competitive edge against experienced rivals.
Expansion delay risks with ₹2,292.21 lakh equipment orders yet to be placed.
Susceptibility to contamination or tampering may cause recalls, penalties, and reputational damage.
Product recalls and liability claims could impose high costs and regulatory consequences.
Heavy reliance on top 10 customers risks significant revenue concentration issues.
Anlon Healthcare Limited Peer Comparison
| Company | CMP (₹) | EPS | P/E Ratio | RONW (%) |
|---|---|---|---|---|
| Anlon Healthcare Limited | [●] | 6.38 | [●] | 25.51 |
| Kronox Lab Sciences Limited | 180.90 | 6.91 | 26.18 | 28.26 |
| Acutaas Chemicals Limited | 1,158.35 | 19.81 | 58.47 | 12.15 |
| Supriya Lifesciences Limited | 683.35 | 23.35 | 29.27 | 18.86 |
